CA3091950A1 - Nouveaux composes sulfonimidoylpurinone substitues en position 7 et derives pour le traitement et la prophylaxie du cancer du foie - Google Patents

Nouveaux composes sulfonimidoylpurinone substitues en position 7 et derives pour le traitement et la prophylaxie du cancer du foie Download PDF

Info

Publication number
CA3091950A1
CA3091950A1 CA3091950A CA3091950A CA3091950A1 CA 3091950 A1 CA3091950 A1 CA 3091950A1 CA 3091950 A CA3091950 A CA 3091950A CA 3091950 A CA3091950 A CA 3091950A CA 3091950 A1 CA3091950 A1 CA 3091950A1
Authority
CA
Canada
Prior art keywords
amino
methyl
oxo
purine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3091950A
Other languages
English (en)
Inventor
Thomas POESCHINGER
Carola Ries
Hong Shen
Hongying Yun
Sabine HOVES
Carina HAGE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA3091950A1 publication Critical patent/CA3091950A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des composés de formule (I), dans laquelle les R1, R2 et R3 sont tels que décrits dans la description, et leurs promédicaments ou sel, énantiomère ou diastéréoisomère pharmaceutiquement acceptables, (destinés à être utilisés) pour le traitement et/ou la prophylaxie du cancer du foie.
CA3091950A 2018-02-28 2019-02-26 Nouveaux composes sulfonimidoylpurinone substitues en position 7 et derives pour le traitement et la prophylaxie du cancer du foie Pending CA3091950A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018077501 2018-02-28
CNPCT/CN2018/077501 2018-02-28
PCT/EP2019/054729 WO2019166432A1 (fr) 2018-02-28 2019-02-26 Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie

Publications (1)

Publication Number Publication Date
CA3091950A1 true CA3091950A1 (fr) 2019-09-06

Family

ID=65685310

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3091950A Pending CA3091950A1 (fr) 2018-02-28 2019-02-26 Nouveaux composes sulfonimidoylpurinone substitues en position 7 et derives pour le traitement et la prophylaxie du cancer du foie

Country Status (19)

Country Link
EP (1) EP3758707A1 (fr)
JP (1) JP7089596B2 (fr)
KR (1) KR20200128414A (fr)
CN (1) CN111801100B (fr)
AR (1) AR114419A1 (fr)
AU (1) AU2019228654A1 (fr)
BR (1) BR112020016509A2 (fr)
CA (1) CA3091950A1 (fr)
CL (1) CL2020002139A1 (fr)
CO (1) CO2020010306A2 (fr)
IL (1) IL276817A (fr)
MA (1) MA52412A (fr)
MX (1) MX2020008746A (fr)
PE (1) PE20211456A1 (fr)
PH (1) PH12020551343A1 (fr)
RU (1) RU2020131012A (fr)
SG (1) SG11202008291XA (fr)
TW (1) TW202003518A (fr)
WO (1) WO2019166432A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112420196A (zh) * 2020-11-20 2021-02-26 长沙市弘源心血管健康研究院 急性心肌梗死患者5年内生存率的预测方法和系统

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
HUE069183T2 (hu) 2018-02-28 2025-02-28 Novartis Ag 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7H--pirrolo[1',2':4,5]pirazino[1,2-b]piridazin-3,5-dion származékok és kapcsolódó vegyületek mint orthomyxovírus repikáció gátlók influenza kezelésére
KR102409595B1 (ko) 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
JP2025522978A (ja) * 2022-07-14 2025-07-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの処置のためのホスホリルプリノン化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
AU2010250923A1 (en) * 2009-05-21 2011-11-17 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
BR112012009329A2 (pt) * 2009-10-22 2016-06-07 Gilead Sciences Inc derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
NZ604423A (en) 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
KR20130108295A (ko) * 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
NZ775222A (en) 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
CR20180229A (es) 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
RU2751349C2 (ru) * 2016-08-29 2021-07-13 Ф. Хоффманн-Ля Рош Аг 7-замещенные сульфонимидоилпуриноны для лечения и профилактики вирусной инфекции
CA3034185A1 (fr) * 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Traitement combine avec un agoniste tlr7 et un inhibiteur d'assemblage de capside du virus de l'hepatite b

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112420196A (zh) * 2020-11-20 2021-02-26 长沙市弘源心血管健康研究院 急性心肌梗死患者5年内生存率的预测方法和系统

Also Published As

Publication number Publication date
IL276817A (en) 2020-10-29
PE20211456A1 (es) 2021-08-05
CN111801100A (zh) 2020-10-20
KR20200128414A (ko) 2020-11-12
CL2020002139A1 (es) 2021-01-04
WO2019166432A1 (fr) 2019-09-06
EP3758707A1 (fr) 2021-01-06
TW202003518A (zh) 2020-01-16
MA52412A (fr) 2021-06-02
BR112020016509A2 (pt) 2020-12-15
CN111801100B (zh) 2023-10-24
MX2020008746A (es) 2020-09-28
RU2020131012A (ru) 2022-03-28
PH12020551343A1 (en) 2021-06-21
CO2020010306A2 (es) 2020-08-31
JP2021514972A (ja) 2021-06-17
AR114419A1 (es) 2020-09-02
JP7089596B2 (ja) 2022-06-22
SG11202008291XA (en) 2020-09-29
AU2019228654A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
AU2021204303B2 (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
AU2020343671C1 (en) RIP1 inhibitory compounds and methods for making and using the same
CN114008037B (zh) 作为kras g12c抑制剂的杂环化合物
CA2774145C (fr) Inhibiteurs de proteases de vhc
CN111801100B (zh) 用于治疗和预防肝癌的7-取代的磺亚氨酰基嘌呤酮化合物和衍生物
CA3095494A1 (fr) Modulateurs de proteolyse et procedes d'utilisation associes
BR112021002479A2 (pt) composto, composição farmacêutica, método para inibir a atividade de itk ou jak3 em uma população de células, método para tratar um distúrbio mediado por itk ou jak3 em um indivíduo necessitando do mesmo e uso de um composto
CA3049175A1 (fr) Inhibiteurs selectifs de jak1
US20200140383A1 (en) 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
CA3133300A1 (fr) Derives de benzodiazepine en tant qu'inhibiteurs de rsv
ES2962774T3 (es) Inhibidores de la replicación de virus de inmunodeficiencia humana
IL296182A (en) Inhibitors of human immunodeficiency virus replication
CN118574834A (zh) 稠合的四环化合物、其组合物和用途
US20200268762A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
TW201736391A (zh) 作為人類鼻病毒抑制劑之炔基核苷類似物
HK40033410A (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
HK40033410B (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
WO2015193229A1 (fr) 1,4-dihydropyrido[3,4-b]pyrazinones inhibitrices de protéine bet, à groupe éther ou amino aromatique meta-substitué
JP2023155223A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びオーロラａ阻害剤を含む治療方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220816